Use of EGFR transactivation inhibitors in human cancer

Details for Australian Patent Application No. 2008249216 (hide)

Owner Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

Inventors Ullrich, Axel; Gschwind, Andreas; Fischer, Oliver; Leserer, Michael; Schafer, Beatrix

Agent Davies Collison Cave

Pub. Number AU-B-2008249216

Parent 2003219029

Filing date 26 November 2008

Wipo publication date 18 December 2008

Acceptance publication date 19 January 2012

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 31/16 (2006.01) - Amides, e.g. hydroxamic acids

A61K 31/381 (2006.01) - having five-membered rings

A61K 38/16 (2006.01) Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61K 38/55 (2006.01) Medicinal preparations containing peptides - Protease inhibitors

Event Publications

11 December 2008 Complete Application Filed

18 December 2008 Application Open to Public Inspection

  Published as AU-B-2008249216

19 January 2012 Application Accepted

  Published as AU-B-2008249216

17 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008249217-Contrast agents for magnetic resonance imaging and methods related thereto

2008249215-A ramp arrangement for a land vehicle